Related Experiment Video

Updated: Sep 10, 2025

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

9.8K

Fyn Kinase: A Potential Target in Glucolipid Metabolism and Diabetes Mellitus

Ruifeng Xiao1, Cong Shen1, Wen Shen1

  • 1Department of Endocrinology and Metabolism, Affiliated Hospital of Jiangsu University, Institute of Endocrine and Metabolic Diseases, Jiangsu University, Zhenjiang 212000, China.

Current Issues in Molecular Biology
|August 27, 2025
PubMed

Insights

The protein Fyn kinase promotes fat accumulation and insulin resistance, contributing to type 2 diabetes and its complications. Inhibiting Fyn may offer a therapeutic strategy for managing diabetes and related metabolic disorders.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Endocrinology

Background:

  • Fyn kinase is involved in cellular processes like growth, survival, and energy metabolism.
  • Fyn kinase dysregulation is linked to insulin resistance, fat accumulation, and diabetic complications.
  • Inflammatory stress, exacerbated by Fyn, is a key factor in diabetes pathogenesis.

Purpose of the Study:

  • To review the role of Fyn kinase in energy metabolism regulation.
  • To explore Fyn's mechanisms in the development of diabetes mellitus and its complications.
  • To identify Fyn as a potential therapeutic target for type 2 diabetes.

Main Methods:

  • Literature review synthesizing existing research on Fyn kinase.
  • Analysis of Fyn's involvement in lipid metabolism and insulin signaling pathways.
  • Examination of Fyn's role in inflammatory pathways relevant to diabetes.

Main Results:

  • Fyn kinase promotes fat accumulation and insulin resistance by inhibiting AMP-activated protein kinase (AMPK).
  • Fyn modulates energy homeostasis via pathways involving CD36, adipocyte differentiation, and insulin signal transduction.
  • Fyn exacerbates inflammation in diabetes through signaling cascades like Akt/GSK-3β/Fyn/Nrf2.

Conclusions:

  • Fyn kinase plays a critical role in regulating glucolipid metabolism and promoting diabetes development.
  • Targeting Fyn kinase presents a promising therapeutic avenue for managing type 2 diabetes mellitus.
  • Understanding Fyn's mechanisms is crucial for developing effective diabetes treatments.
Keywords:
Fyn kinasediabetes mellitusdiabetic complicationsglucolipid metabolisminflammationinsulin

More Related Videos

A Model of Chronic Nutrient Infusion in the Rat08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.8K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.1K

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.5K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.6K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
334